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1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in
uremia. The effect of intravenous 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] therapy on insulin and lipid metabolism was examined in
patients on maintenance hemodialysis (HD). Eight patients (Group I,
19 6 1 years old) were studied before and after four weeks of intravenous
1,25 (OH)2D3 therapy (1.8 6 0.3 mg), during which time the serum
parathyroid hormone (PTH) concentrations did not change. Another
eight patients (Group II, 18 6 1 years old) were studied before and after
four weeks of oral dihydrotachysterol (0.8 6 0.1 mg). Serum PTH also did
not change in Group II. Serum glucose concentrations during an oral
glucose tolerance test (OGTT) were higher in Group I before
1,25(OH)2D3 compared with controls and these normalized following four
weeks of intravenous 1,25(OH)2D3. Serum glucose concentrations during
OGTT were also higher in Group II before DHT compared with controls
and did not change following four weeks of oral DHT. Insulin sensitivity
during euglycemic clamp studies in Group I before 1,25(OH)2D3 (223 6
20 mg/m2/min; P , 0.01) was low compared with controls (320 6 26
mg/m2/min) and was normalized following therapy (315 6 25 mg/m2/min).
Insulin sensitivity was also low in Group II at the beginning of the study
and did not change at the end of the four week period. Both early-phase
and late-phase insulin secretion were low in Group I before 1,25(OH)2D3
compared with controls and normalized following intravenous
1,25(OH)2D3 therapy. Both early-phase and late-phase insulin secretion
were also low in Group II at the beginning of the study and did not change
at the end of the four week period of DHT treatment. Plasma triglycerides
were elevated in Group I patients before treatment (198 6 16 mg/dl; P ,
0.01) compared with controls (139 6 12 mg/dl) and were normalized
(148 6 13 mg/dl) following intravenous 1,25(OH)2D3 therapy. Plasma
total cholesterol and high density lipoprotein cholesterol were normal
before treatment compared with controls and did not change following
intravenous 1,25(OH)2D3 therapy. Plasma triglycerides, total cholesterol
and high density lipoprotein cholesterol did not change in Group II during
the study period. Thus, intravenous 1,25(OH)2D3 therapy corrected
glucose intolerance, insulin resistance, hypoinsulinemia as well as hyper-
triglyceridemia in patients on HD, in the absence of PTH suppression.
Insulin resistance, as evidenced by reduced peripheral sensitiv-
ity to the hypoglycemic action of insulin, is common in patients
with uremia on dialysis [1]. Defects in insulin secretion have also
been reported in these patients [2]. Insulin abnormalities in
uremic patients may contribute to hypertriglyceridemia by impair-
ing lipoprotein lipase activity [3]. These metabolic complications
may represent important risk factors for accelerated atheroscle-
rosis in these patients [4], however, the etiology of insulin
abnormalities in uremia remains unclear. 1,25-Dihydroxyvitamin
D3 [1,25(OH)2D3] is an important modulator of insulin release
from pancreatic islets [5]. Intravenous 1,25(OH)2D3 corrects
glucose intolerance and stimulates insulin secretion in response to
a glucose challenge in 1,25(OH)2D3 deficient animals [6].
1,25(OH)2D3 deficiency is a common complication in patients on
dialysis and may contribute to the pathogenesis of insulin abnor-
malities in uremia [7]. Intravenous 1,25(OH)2D3 has been suc-
cessfully used to treat severe secondary hyperparathyroidism in
dialysis patients [8]. Kautzky-Willer et al reported normalization
of insulin sensitivity in patients on hemodialysis after 12 weeks of
intravenous 1,25(OH)2D3 therapy [9]. However, since there was
also a significant reduction in parathyroid hormone (PTH) levels
in these patients, the authors could not differentiate between the
actions of 1,25(OH)2D3 per se or those of PTH reduction. The
effect of four weeks of intravenous 1,25(OH)2D3 therapy on
insulin and lipid metabolism was examined in patients on hemo-
dialysis, during which time the PTH concentrations did not
change, so that the direct actions of 1,25(OH)2D3 could be
assessed independently.
METHODS
Sixteen patients (19 6 1 years old) with uremia who were on
hemodialysis (HD) were studied. The underlying diagnosis in-
cluded focal segmental glomerulosclerosis, renal dysplasia, reflux
nephropathy, obstructive uropathy and unknown etiology. They
received HD three to four hours per session, three sessions a
week. These patients had all been stabilized on HD for at least six
months prior to entering the study. They had previously been on
oral dihydrotachysterol (DHT) but developed moderate to severe
hyperparathyroidism despite DHT treatment. All 16 patients had
their DHT discontinued for two weeks prior to the study. Eight
patients (Group I, 18 6 1 years old) were studied before and after
four weeks of intravenous 1,25(OH)2D3 therapy at 1.8 6 0.3 mg
(range 1.5 to 2.5 mg) three times weekly. The other eight patients
(Group II, 19 6 1 years old) were restarted on DHT at 0.8 6 0.1
mg (range 0.5 to 1 mg) daily, and were also studied in the same
way before and after four weeks of oral DHT. Other oral
medications in both groups of patients included calcium carbon-
ate, sodium bicarbonate, antihypertensives in the form of long
acting nifedipine and water-soluble vitamins (Nephrovite; R & D
Laboratories, Inc., Marina Del Rey, CA, USA). Both groups of
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patients were also treated with intravenous erythropoietin for
anemia and had stable hematocrits for at least three months prior
to the present study. There were no changes in other medications
or in the dialysis prescription (including dialysate calcium concen-
trations) during the four weeks of intravenous 1,25(OH)2D3
therapy. None of the patients was on corticosteroids at the time or
had been on corticosteroids for six months before the study. None
patients and controls had a history of or family history of diabetes
mellitus. Their daily intake of carbohydrate was more than 200 g
and their body weights were stable for at least two months prior to
the studies. Their dietary intakes of sodium (2 g/day), potassium
(2 g/day) and phosphorus (800 mg) were restricted but the intake
of protein was not. Dietary intakes were assessed monthly using a
three-day dietary recall and adjustments made if necessary. Con-
trols consisted of seven healthy subjects (age 19 6 1 years old)
who consumed regular weight-maintaining diets and took no
medications. They did not have history of any significant illness or
any family history of diabetes mellitus. All patients and controls
were free from infections at the time of the studies. All studies
were started about 9 a.m. after an overnight fast of about 10 to 12
hours. The patients were studied just before a scheduled HD
session. The patients and controls sat comfortably in a reclining
chair and were not allowed to eat or drink apart from water during
the studies. The study was approved by the Committee for Clinical
Investigations at the Children’s Hospital of Los Angeles where the
clinical studies were performed. The purpose and potential risks
of the study were carefully explained to all patients and subjects,
and written informed consent was obtained before their partici-
pation.
Oral glucose tolerance tests
Oral glucose tolerance tests were performed in the morning
after an overnight fast. After obtaining at least two serum samples
for fasting glucose and insulin concentrations, an oral dose of
glucose at 75 g was given. Thereafter, blood samples were
obtained for determination of plasma glucose and insulin concen-
trations at 30, 60, 90 and 120 minutes. The serum glucose
concentrations after oral glucose were used as indices of glucose
tolerance.
Euglycemic clamp studies
Insulin sensitivity was measured by the hyperinsulinemic eugly-
cemic clamp technique [10]. Two intravenous line were started in
contralateral arms. One intravenous line was inserted in a vein on
the dorsum of the hand, kept patent by a slow intravenous
infusion of normal saline and used for blood sampling. This hand
was placed in a heated box (65°C) to arterialize the blood [11]. An
indwelling catheter was placed in a vein in the opposite arm for
infusion of glucose and insulin. After obtaining at least three
fasting serum samples for glucose and insulin concentration, a
prime-continuous infusion of insulin was given intravenously at 40
mU/m2/min of body wt to acutely raise and maintain the serum
insulin concentrations at a plateau of around 100 mU/ml for 120
minutes. Serum glucose concentration was measured at five
minute intervals, and a variable infusion of 20% dextrose was
adjusted to maintain the glucose concentration at fasting levels.
Serum was also obtained every ten minutes for measurement of
insulin concentrations. Under steady state conditions of euglyce-
mia and hyperinsulinemia during the euglycemic clamp study, the
rate of glucose infusion provides an index of insulin-stimulated
glucose metabolism and is used as an index of insulin sensitivity
(mg/m2/min).
Hyperglycemic clamp studies
Insulin secretion was measured by the hyperglycemic clamp
technique as previously described [10]. Patient preparation was
similar to the euglycemic clamp. A priming dose of 20% dextrose
was given to acutely raise blood glucose concentration at 125
mg/dl (6.9 mmol/liter) above fasting glucose concentrations. Con-
stant hyperglycemia at this level was then maintained for 120
minutes by varying the infusion of 20% dextrose but no insulin. In
the first 10 minutes of the study, blood was taken at two-minute
intervals for the measurement of serum glucose and insulin. The
mean concentration of serum insulin in the first 10 minutes in an
index of early-phase insulin secretion Ie (mU/ml) in response to
hyperglycemia. Thereafter, blood was taken every five minutes for
the measurement of serum glucose and every 10 minutes for the
measurement of serum insulin. The mean serum insulin concen-
tration during the hyperglycemic clamp study, at 10-minute inter-
vals from 20 to 120 minutes, was an index of late-phase insulin
secretion I (mU/ml) under steady state conditions of constant
hyperglycemia.
Biochemical measurements
Serum glucose concentration was measured by the glucose
oxidase method using a Yellow Springs 23 AM glucose analyzer
(Yellow Springs Instruments, OH, USA). Serum immunoreactive
insulin concentration was measured by double antibody radioim-
munoassay (Pharmacia, Uppsala, Sweden). Intact serum parathy-
roid hormone (PTH) was measured by an immunoradiometric
assay (Nichols, San Juan Capistrano, CA, USA). Serum
1,25(OH)2D3 was measured by a radioreceptor assay (Nichols).
This assay is specific for both 1,25(OH)2D3 and 1,25(OH)2D2, and
involves a preliminary extraction and purification of serum using
a single column containing a C18OH activated matrix. Once
purified, the material was quantitated in a radioreceptor assay
using a calf thymus receptor and tritiated 1,25(OH)2D3. Separa-
tion of bound from free 1,25(OH)2D3 was achieved by incubation
with dextran coated charcoal. Fasting lipid and lipoprotein values
were determined from fresh plasma samples. Lipoprotein frac-
tionation was performed with ultracentrifugation and selective
precipitation. Triglycerides and cholesterol from whole plasma
and cholesterol from lipoprotein fractions were assayed by auto-
mated enzymatic methods. Serum total calcium, phosphorus,
potassium, magnesium, creatinine and blood urea nitrogen were
measured by standard methods on a multichannel autoanalyzer.
All values are expressed as mean 6 SEM. The data were tested
for normality using the chi square method. Analysis of variance
and Student t-tests for paired and unpaired observations were
used for analysis of the results. Statistical significance was recog-
nized at the 5% level.
RESULTS
All patients tolerated the 1,25(OH)2D3 therapy well without
any clinical side effects. There were no significant changes in
weight, height, mean arterial blood pressure, caloric intake or
hemoglobin concentrations. The biochemical data in these pa-
tients before and after the two weeks of 1,25(OH)2D3 therapy are
presented in Table 1. There was a significant decrease in serum
glucose and a significant increase in serum insulin in Group I
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patients following 1,25(OH)2D3. There was also a significant
increase in serum 1,25(OH)2D3 concentrations after therapy.
There were no other differences in the serum biochemical param-
eters measured. There were no differences in any biochemical
parameters in Group II before and after four weeks of oral DHT.
There was no difference in dietary calcium intake and dialytic
calcium concentration in the two groups of patients during the
study period.
Before treatment, fasting serum glucose concentrations were
higher in both groups of patients compared with controls. Serum
glucose concentrations during oral glucose tolerance test (OGTT)
were higher in Group I before 1,25(OH)2D3 compared with
controls and these normalized following four weeks of intrave-
nous 1,25(OH)2D3. Serum glucose concentrations during OGTT
were also higher in Group II before DHT compared with controls
and did not change following four weeks of oral DHT (Fig. 1).
Thus, intravenous 1,25(OH)2D3 normalized glucose intolerance
whereas oral DHT did not affect glucose tolerance in patients on
HD.
Insulin sensitivity during the euglycemic clamp studies in Group
I patients before 1,25(OH)2D3 (242 6 20 mg/m
2/min; P , 0.01)
was low compared with controls (320 6 26 mg/m2/min) and was
normalized following therapy (315 6 25 mg/m2/min). Insulin
sensitivity did not change in Group II patients after DHT and
remained low compared with controls. There was no difference in
the steady-state insulin concentrations during the studies in
Group I and II patients or those the studies in controls (Fig. 2).
Both early-phase and late-phase insulin secretion were low in
Group I before 1,25(OH)2D3 compared with controls and nor-
malized following intravenous 1,25(OH)2D3 therapy. Both early-
phase and late-phase insulin secretion were also low in Group II
at the beginning of the study and did not change at the end of the
four week period (Fig. 3).
Plasma triglycerides were elevated in Group I before treatment
(198 6 16 mg/dl; P , 0.01) compared with controls (139 6 12
mg/dl) and were also normalized (148 6 13 mg/dl) following
intravenous 1,25(OH)2D3 therapy. Plasma total cholesterol
(182 6 15 mg/dl) and high density lipoprotein cholesterol (45 6 5
mg/dl) were normal before treatment compared with controls
(170 6 13 mg/dl and 52 6 6 mg/dl, respectively) and did not
change following intravenous 1,25(OH)2D3 therapy. Plasma trig-
lycerides were also elevated whereas plasma total cholesterol and
high density lipoprotein cholesterol were normal in Group II
before treatment. These lipid values did not change significantly
following four weeks of treatment with oral DHT.
DISCUSSION
Insulin resistance is very common in patients with uremia who
are on dialysis. In about half of the patients, glucose tolerance
remains normal because the pancreatic beta cell is able to
augment its secretion of insulin to offset the insulin resistance.
The other half of the patients have insulin secretion abnormalities
in addition to insulin resistance and therefore manifest intoler-
ance to glucose loads. There is evidence that either secondary
hyperparathyroidism and/or vitamin D deficiency may contribute
to the defects in glucose-stimulated insulin secretion and sensitiv-
ity in patients with end-stage renal disease. Treatment of hyper-
parathyroidism in uremic patients, either surgically [12] or medi-
cally [13], led to the correction of glucose intolerance, an increase
in insulin secretion and no change in insulin sensitivity. Akmal et
al examined the effect of hyperparathyroidism on insulin metab-
olism in uremia by parathyroidectomy in a uremic dog model and
came to the same conclusion [14]. Pharmacological doses of
intravenous 1,25(OH)2D3, given acutely, corrected glucose intol-
erance and increased insulin secretion [15] in 1,25(OH)2D3-
deficient hyperparathyroid hemodialysis patients without chang-
ing serum PTH concentrations. Recently, Kautzky-Willer et al
reported normalization of insulin sensitivity in patients on hemo-
dialysis after 12 weeks of intravenous 1,25(OH)2D3 therapy [9].
However, since there was also a significant reduction in parathy-
roid hormone (PTH) levels in these patients, the authors could
not differentiate between the actions of 1,25(OH)2D3 per se or
those of PTH reduction. Also, in the latter study, there was no
control group of HD patients not receiving intravenous
1,25(OH)2D3 therapy. Hemodialysis, per se, has been known to
improve insulin sensitivity [16, 17]. Thus, it was not clear whether
the improvement in insulin sensitivity could be due in part to the
cumulative effects of HD.
Both Group I and Group II from the present study were
1,25(OH)2D3 deficient and severely hyperparathyroid at the be-
ginning of the study. They also had fasting hyperglycemia, glucose
intolerance, insulin resistance and hypoinsulinemia. These abnor-
malities in glucose and insulin metabolism were typical of patients
with end-stage renal disease on HD [1, 2] and could result from
either vitamin D deficiency or secondary hyperparathyroidism.
Following intravenous 1,25(OH)2D3 for four weeks in Group I
patients, serum 1,25(OH)2D3 were normalized with no changes in
serum PTH concentrations. At the same time, glucose intoler-
ance, insulin resistance and hypoinsulinemia were normalized.
The control group of patients (Group II) received oral DHT for
four weeks since it was unethical to manage them without any
vitamin D supplements. They remained vitamin D deficient and
hyperparathyroidic and did not show any improvement in insulin
and glucose metabolism. Thus, 1,25(OH)2D3 deficiency rather
than secondary hyperparathyroidism is the likely cause of the
glucose and insulin abnormalities in this study. Alternatively,
pharmacological effects of intravenous 1,25(OH)2D3 therapy
could also be a possible mechanism for the correction of these
Table 1. Biochemical data in patients on hemodialysis before and after
4 weeks of treatment with intravenous 1,25(OH)2D3 (Group I); Group
II were studied before and after 4 weeks of oral DHT
Group I Group II
Before After Before After
Ca mg/dl 9.1 6 0.2 9.5 6 0.2 9.2 6 0.2 9.3 6 0.2
PO4 mg/dl 6.3 6 0.3 6.6 6 0.3 6.7 6 0.3 6.5 6 0.3
HCO3 mmol/liter 23 6 1 24 6 1 22 6 1 23 6 1
Albumin g/dl 3.7 6 0.1 3.6 6 0.1 3.5 6 0.1 3.4 6 0.1
BUN mg/dl 79 6 10 76 6 9 81 6 10 78 6 8
Creatinine mg/dl 10.6 6 0.9 10.8 6 1.0 10.3 6 0.9 10.1 6 0.9
PTH pg/ml 798 6 90 763 6 101 752 6 98 739 6 96
1,25(OH)2D3 pg/ml 12 6 3 36 6 6
a 10 6 3 11 6 3
Fasting glucose mg/dl 103 6 5 88 6 4a 101 6 5 102 6 5
Fasting insulin mU/ml 7 6 1 12 6 1a 8 6 1 7 6 1
Triglycerides 198 6 16 148 6 13a 203 6 18 208 6 20
Total cholesterol 182 6 15 175 6 14 188 6 18 191 6 15
HDL cholesterol 45 6 5 48 6 6 46 6 5 43 6 4
a p , 0.05 compared with before treatment values
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metabolic abnormalities. Group I and Group II patients had
similar degrees of insulin resistance before the study and were
observed over the same period of time with similar HD prescrip-
tions. Therefore, the improvement in insulin sensitivity is unlikely
to be due to the cumulative effects of HD.
Both Group I and Group II patients had isolated hypertriglyc-
eridemia at the beginning of the study. This lipid profile is the
most common among patients with end-stage renal disease on
dialysis [3, 18]. Hypertriglyceridemia was corrected following
normalization of insulin abnormalities after four weeks of intra-
venous 1,25(OH)2D3 therapy. Indeed, insulin abnormalities in
uremic patients may contribute to hypertriglyceridemia by impair-
ing lipoprotein lipase activity [3]. It is also possible that correction
of vitamin D deficiency and/or pharmacologic effects of intrave-
nous 1,25(OH)2D3 therapy may contribute to this improvement in
lipid metabolism. Furthermore, secondary hyperparathyroidism
has been proposed as a potential cause of lipid abnormalities in
end-stage renal failure [14]. However, since hypertriglyceridemia
was corrected without any changes in PTH concentrations, this
latter possibility is unlikely in the present study. Whether correc-
tion of hypertriglyceridemia after intravenous 1,25(OH)2D3 ther-
apy will lead to an actual decrease in long-term cardiac morbidity
in patients undergoing HD remains to be tested.
In summary, intravenous 1,25(OH)2D3 therapy corrected glu-
cose intolerance, insulin resistance, hypoinsulinemia as well as
hypertriglyceridemia in patients on HD, in the absence of PTH
suppression. Correction of vitamin D deficiency and/or pharma-
cologic effects of intravenous 1,25(OH)2D3 were the likely causes
Fig. 1. Serum glucose concentrations during oral glucose tolerance tests
in Group I and Group II before and after the four-week treatment period,
and in normal controls. In A symbols are: (L) before (E) after i.v.
1,25(OH)2D3; *P , 0.05 vs. control values; #P , 0.05 vs. before vitamin
D values. In B symbols are: (L) before oral dihydrotachysterol (DHT);
(E) after oral DHT. Symbol (M) in C is controls.
Fig. 2. Insulin sensitivity, measured by insulin stimulated glucose me-
tabolism during euglycemic clamp studies in Group I and Group II before
(M) and after (f) the four-weeks treatment period, and in normal
controls ( ). *P , 0.01 vs. control values; #P , 0.01 vs. before vitamin D
values. The bottom panel represents the mean serum insulin concentra-
tions during the euglycemic clamps.
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of improvement in insulin and lipid abnormalities in these pa-
tients with end-stage renal disease who were on HD.
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